Article

AAO: Don’t let patients self-medicate with marijuana to treat glaucoma

The American Academy of Ophthalmology is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

 

San Francisco-The American Academy of Ophthalmology is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

Based on analysis by the National Eye Institute and the Institute of Medicine, the Academy said that it finds “no scientific evidence that marijuana is an effective long-term treatment for glaucoma, particularly when compared to the wide variety of prescription medication and surgical treatments available.”

The Academy also caution that marijuana has side effects that could further endanger the user's eye health.

Initial studies in the 1970s reported that smoking marijuana or administering it orally or intravenously-but not topically applied to the eye-did lower IOP for 3 to 4 hours, but, according to the Academy, there is no evidence to date that proves it alters the long-term course of the disease.

 

“Glaucoma medication and surgical treatments-which are scientifically proven to be effective and safe for daily use -also do not have the negative side effects of marijuana,” the Academy said in a prepared statement.

In addition, the Academy said marijuana lowers blood pressure throughout the body, resulting in the potential to lower the blood flow to the optic nerve which can lead to vision loss. This could effectively cancel out the benefit of a lowered IOP.

People who smoke marijuana also increase their risk for cancer and eye diseases.

Those who have glaucoma and are considering using marijuana to treat the disease are strongly urged to consult an ophthalmologist about the risks, the Academy said.

 

"Ophthalmologists are focused on providing treatments that will give patients the very best results," said Gregory L. Skuta, MD, glaucoma specialist and president of the Academy. "For glaucoma, this means recommending therapies that have been proven to safely alter the course disease over a long-term period, such as medicated eye drops or surgery.

“No research exists to date that demonstrates that marijuana can deliver this level of efficacy,” he said.

 

READ MORE: How long-time club drug is now being linked to eye damage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.